CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hengrui's HRS/BHB-1893 Improves Exercise Capacity in 52-Week Phase 2 Extension Study

By Public Technologies
  • Hengrui Pharma and Braveheart Bio presented HRS/BHB-1893 Phase 2 extension results on November 6, 2026, at American Heart Association Scientific Sessions.
  • The 52-week extension enrolled 42 adults with symptomatic obstructive hypertrophic cardiomyopathy.
  • The investigational drug improved exercise capacity and patient-reported symptoms, with sustained reductions in obstruction to blood flow from the heart.
  • No severe or serious adverse events occurred during treatment; two patients resumed treatment at lower doses following temporary declines in heart function.
  • Most patients remained on the starting dose, supporting a simpler dosing approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk